Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for refractory non-infectious non-anterior uveitis
2022-000366-18Phase 3Active
- Sponsor
- Rouen University Hospital
- Start
- Jun 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of baricitinib in uveitis, sponsored by Rouen University Hospital. Primary endpoint: Complete remission at 6 months. Started Jun 2022; status: active.
02
Drugs
baricitinib
03
Conditions
uveitis
Beyond the preview
Go deeper on 2022-000366-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000366-18.